What is MIMs?
Founded in 2016 and headquartered in Quebec, Canada, MIMs specializes in providing pharmaceutical enterprises with sophisticated, interactive augmented intelligence platforms. By facilitating precise biological simulations during the critical early stages of drug development, the company empowers scientists to accelerate the discovery of targeted and personalized therapies. MIMs occupies a vital niche in the life sciences sector, bridging the gap between complex computational biology and actionable clinical insights. Its platform is designed for seamless integration, allowing organizations of varying sizes to leverage high-fidelity data modeling to reduce development timelines and improve therapeutic efficacy.
How much funding has MIMs raised?
MIMs has raised a total of $5M across 1 funding round:
Other Financing Round
$5M
Other Financing Round (2021): $5M with participation from Real Ventures, Medteq, Desjardins Capital, Anges Québec, StandUp Ventures, and Anges Québec Capital
Key Investors in MIMs
Real Ventures
A venture capital firm that supports mission-driven entrepreneurs by providing stage-specific guidance and fostering communities for global operational success.
StandUp Ventures
A Toronto-based venture capital fund established in 2017 that focuses on providing capital to high-growth technology ventures.
Desjardins Capital
A prominent investment firm providing long-term capital and strategic support to businesses across various sectors to drive sustainable economic growth.
What's next for MIMs?
With this major enterprise-level funding, MIMs is poised to transition into a phase of rapid commercial expansion and product refinement. The strategic allocation of these resources will likely focus on enhancing the predictive accuracy of its biological simulation engines and broadening its client base across international markets. As the pharmaceutical industry increasingly pivots toward data-centric R&D, MIMs is strategically aligned to become an indispensable partner for firms seeking to optimize their drug development pipelines through advanced machine learning and systems biology. Future growth will likely involve deepening its integration with existing laboratory workflows and exploring new therapeutic modalities.
See full MIMs company page
